cheap propecia

Publications

Les chercheurs de l’Unité sont reconnus mondialement et fréquemment invités comme conférenciers, tant à l’échelle nationale qu’internationale, afin de présenter leurs travaux et/ou à discuter des traitements ainsi que des nouvelles approches thérapeutiques reliées à cette maladie. De plus, des prix d’excellence de renommée internationale ont été décernés à plusieurs chercheurs de l’Unité pour la qualité et l’originalité de leurs travaux.

Voici une courte liste de publications récentes et pertinentes.

Éditorial

  1. Roubille, C., Martel-Pelletier, J., Pelletier, J.P.: Osteoarthritis treatments: where do we stand at the moment? Medicographia 35(2):172-180, 2013.
  2. Pelletier, J.P., Martel-Pelletier, J.: Un traitement qui guérit l’arthrose : le rêve deviendra t’il réalité? Le Patient 5(5)12-15, 2011 http://www.lepatient.ca/archives.htm#vol5no5

Livres

  1. Martel-Pelletier, J., Pelletier, J.P.: Éditeurs, In: Addressing Unmet Needs in Osteoarthritis. Future Medicine ltée, Londres, Royaume-Uni. 2012, 157 pages.
  2. Martel-Pelletier, J., Pelletier, J.P.: Éditeurs, In: Understanding Osteoarthritis From Bench to Bedside, Research Signpost, Kerala, India, 2011, pp 1-144 http://issuu.com/researchsignpost/docs/pelletier_ebook
  3. Reginster, J.Y., Pelletier, J.P., Martel-Pelletier, J., Éditeurs invites, In: TherapyThemed content: Osteoarthritis, Future Medicine, London, England 7(6):575-718, 2010.

Chapitres de livre et Revues

  1. Roubille, C., Pelletier, J.P., Martel-Pelletier, J.: Drug/Agent Treatments for Osteoarthritis – Present and Future. In: Osteoarthritis: Pathogenesis, diagnosis, available treatments, drug safety, regenerative and personalized medicine. Kapoor, M. et Mahomed, N.N., eds. Springer. New York, NY, É.-U. Chapitre 10, pp 191-210, 2015.
  2. Roubille, C., Pelletier, J.P., Martel-Pelletier, J.: New and emerging treatments for osteoarthritis management: will the dream come true with personalized medicine? Expert Opin Pharmacother. 14(15):2059-2077, 2013.
  3. Roubille, C., Martel-Pelletier, J., Haraoui, B., Tardif, J.C., Pelletier, J.P.: Biologics and the cardiovascular system: a double edged sword. Antiinflamm. Antiallergy Agents Med. Chem. 12(1):68-82, 2013.
  4. Martel-Pelletier, J., Wildi, L.M., Pelletier, J.P.: Future therapeutics for osteoarthritis. Bone 51:297-311, 2012.
  5. Martel-Pelletier, J., Pelletier, J.P.: The importance of bone in the osteoarthritis process: Is there a relationship with osteoporosis? In: Osteoporosis and Other Bone Diseases. Arinoviche, R. and Arriagada, M. Eds. Fundación Chilena de Osteoporosis. Santiago, Chile, chapitre 34, pp 491-503, 2011.
  6. Kapoor, M., Martel-Pelletier, J., Lajeunesse, D., Pelletier, J.P., Fahmi, H.: Role of pro-inflammatory cytokines in the pathophysiology of osteoarthritis. Nat. Rev. Rheumatol. 7:33-42, 2011.
  7. Pelletier, J.P., Martel-Pelletier, J., Wildi, L.M., Raynauld, J.P. : Long term knee OA trial design : an ounce of prevention is worth a pound of cure. http://ard.bmj.com/letters (eLetter en ligne; 1 octobre 2010).

 Articles scientifiques

  1. Martel-Pelletier, J., Roubille, C., Abram, F., Hochberg, M.C., Dorais, M., Delorme, P., Raynauld, J.P., Pelletier, J.P.: First line analysis of the effects of treatment on progression of structural changes in knee osteoarthritis over 24 months: data from the osteoarthritis initiative progression cohort. Ann. Rheum. Dis. 74(3):547-56, 2015.
  2. Pelletier, J.P., Roubille, C., Raynauld, J.P., Abram, F., Dorais, M., Delorme, P., Martel-Pelletier, J.: Disease modifying effect of strontium ranelate in a subset of patients from the Phase III knee osteoarthritis study SEKOIA using quantitative MRI: reduction in bone marrow lesions protects against cartilage loss. Ann. Rheum. Dis. 74(2):422-9, 2015.
  3. Roubille, C., Martel-Pelletier, J., Abram, F., Dorais, M., Delorme, P., Raynauld, J.P., Pelletier, J.P.: Impact of disease treatments on the progression of knee osteoarthritis structural changes related to meniscal extrusion: Data from the OAI progression cohort. Semin. Arthritis Rheum. 45(3):257-67, 2015.
  4. Roubille, C., Raynauld, J.P., Abram, F., Paiement, P., Dorais, M., Delorme, P., Bessette, L., Beaulieu, A.D., Martel-Pelletier, J., Pelletier, J.P.: The presence of meniscal lesions is a strong predictor of neuropathic pain in symptomatic knee osteoarthritis: a cross sectional pilot study. Arthritis Res. Ther. 16(6):507, 2014.
  5. Raynauld, J.P., Martel-Pelletier, J., Dorais, M., Haraoui, B., Choquette, D., Abram, F., Beaulieu, A., Bessette, L., Morin, F., Wildi, L.M., Pelletier, J.P.: Total knee replacement as a knee osteoarthritis outcome: predictors derived from a 4 year long-term observation following a randomized clinical trial using chondroitin sulfate. Cartilage 4(3):219-226, 2013.
  6. Raynauld, J.P., Martel-Pelletier, J., Haraoui, B., Choquette, D., Dorais, M., Wildi, L.M., Abram, F., Pelletier, J.P. for the Canadian Licofelone Study Group.: Risk factors predictive of joint replacement in a two-year multicentre clinical trial in knee osteoarthritis using MRI: results from over six years of observation. Ann. Rheum. Dis. 70:1382-1388, 2011.
  7. Wildi, L.M., Raynauld, J.P., Martel-Pelletier, J., Beaulieu, A., Bessette, L., Morin F., Abram, F., Dorais, M., Pelletier J.P. : Chondroitin sulphate reduces both cartilage volume loss and bone marrow lesions in knee OA patients starting as early as 6 months after initiation of therapy: a randomized, double-blind, placebo controlled pilot study using MRI. Ann. Rheum. Dis. 70:982-989, 2011 (un éditorial soulignant l’importance de ce travail a été publié dans: Focus on Alternative and Complementary Therapies 16:311-312, 2011).
  8. Dodin, P., Pelletier, J.P., Martel-Pelletier, Abram, F.: Automatic human knee cartilage segmentation from 3D magnetic resonance images. IEEE Trans. Biomed. Eng. 57:2699-2711, 2010.
  9. Pelletier, J.P., Raynauld, J.P., Caron, J., Mineau, F., Abram, F., Dorais, M., Haraoui, B., Choquette, D., Martel-Pelletier, J.: Decrease in serum level of matrix metalloproteinases is predictive of the disease-modifying effect of osteoarthritis drugs assessed by quantitative MRI in patients with knee osteoarthritis. Ann. Rheum. Dis. 69:2095-2102, 2010.
  10. Raynauld, J.P., Martel-Pelletier, J., Bias, P., Laufer, S., Haraoui, B., Choquette, D., Beaulieu, A.D., Abram, F., Dorais, M., Vignon, E., Pelletier, J.P., and the Canadian Licofelone Study Group: Protective effects of licofelone, a 5-lipoxygenase and cyclooxygenase inhibitor, versus naproxen on cartilage loss in knee osteoarthritis: A first multicentre clinical trial using quantitative MRI. Ann. Dis. Rheum. 68:938-947, 2009 (article présenté comme une avancée majeure en recherche dans Nat. Clin. Pract. Rheumatol. 4:565-566, 2008).